Weekly subcutaneous injection of tocilizumab in patients with rheumatoid arthritis

References

• Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010;20:539–47.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50.
   PubMed Web of Science ®Google Scholar
• Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rhaumatology (Oxford, England). 2015;54:672–7.
   PubMed Web of Science ®Google Scholar
• Hirano Y, Takemoto G, Okada T, Ojima M, Oishi Y. Add-on of tacrolimus in rheumatoid arthritis patients with inadequately response to tocilizmab treatment. Cent J Orthop traumat. 2014;57:373–4.
   Google Scholar
• Kaneshiro S, Ebina K, Hirao M, Tsuboi H, Nishikawa M, Nampei A, et al. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod Rheumatol. 2017;27:42–9.
   PubMed Web of Science ®Google Scholar
• Ito S, Takai C, Kobayashi D, Murasawa A, Narita I, Nakazono K. The effect of iguratimod and switching from the subcutaneous injection to the intravenous injection of tocilizumab in a patient with rheumatoid arthritis. J Clin Rheumatol Rel Res., in press.
   Google Scholar
• Ito S, Kobayashi D, Kodama A, Oyakawa T, Harigane K, Abe A, et al. Analysis of the effect of tocilizumab (TCZ) after etanercept (ETN): the influence of increasing of the dose of prednisolone (PSL). Rheumatology. 2015;54:567–74.
   PubMed Web of Science ®Google Scholar
• Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol. 2015;42:799–809.
   PubMed Web of Science ®Google Scholar
• Ogata A, Atsumi T, Fukuda T, Hirabayashi Y, Inaba M, Ishiguro N, et al. Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015;67:1354–62.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ito S, Takai C, Nomura Y, Nemoto T, Lee H, et al. The efficacy of tocilizumab subcutaneous injection in rheumatoid arthritis patients treated with intravenous tocilizumab. Rheumatology 2016;56:537–40.
   Google Scholar
• Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:1653–61.
   PubMed Web of Science ®Google Scholar
• Burmester GR1, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomized, double-blind, parallel-group study and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73:69–74.
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanaka Y, Ishii T, Kurimoto S, et al. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: results of the 12-week double-blind period. Mod Rheumatol. 2018;28:76–84.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19:64–8.
   PubMed Web of Science ®Google Scholar
• Hoshi D, Nakajima A, Inoue E, Shidara K, Sato E, Kitahama M, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012;22:122–7.
   PubMed Web of Science ®Google Scholar
• Ito S, Kobayashi D, Narita I, Kobayashi T, Yoshie H, Murasawa A, Nakazono K. Management of biologics induced infection: introduction of tocilizumab, education of patients and medical cooperation. Rheumatology. 2015;53:96–104.
   Google Scholar
• Nagamine R, Chen W, Kondo K. White blood cell counts before and after tocilizumab administration. Kyusyu J Rheumatol. 2011;31:31–4.
   Google Scholar
• Nakamura I, Koizumi Y, Ito K. Change of the number of white blood cells in rheumatoid arthritis patients treated with tocilizumab. Naika. 2011;108:739–42.
   Google Scholar
• Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002;61:161–6.
   PubMed Web of Science ®Google Scholar
• Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507–12.
   PubMed Web of Science ®Google Scholar
• Suwa T, Hogg JC, Klut ME, Hards J, van Eeden SF. Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med. 2001;163:970–6.
   PubMed Web of Science ®Google Scholar
• Legendre F, Bogdanowicz P, Boumediene K, Pujol JP. Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol. 2005;32:1307–16.
   PubMed Web of Science ®Google Scholar
• Hashizume M, Mihara M. Desirable effect of combination therapy with high molecular weight hyaluronate and NSAIDs on MMP production. Osteoarthr Cartil. 2009;17:1513–18.
   PubMed Web of Science ®Google Scholar
• Ito S. Analysis of the spacing of the intravenous administration of tocilizumab in patients with rheumatoid arthritis. J Chub Rheum Assoc. 2016;46:5–7.
   Google Scholar